Shots::stohthShots:

• Novartis to initiate P-III CAN-COVID study assessing the efficacy of canakinumab vs PBO on top of SOC in patients with COVID-19 pneumonia with its anticipated results in late summer 2020
• The company plans to enroll 450 patients across France- Germany- Italy- Spain- UK and the US with an aim to evaluate canakinumab + SoC in increasing the chance of survival without the need for invasive mechanical ventilation among patients with COVID-19 pneumonia
• The initiation of the study is a part of the Novartis approach to applying its best science in tackling the COVID-19 pandemic. Canakinumab is an IL-1β blocker having a potential to treat severe immune overreaction called cytokine release syndrome (CRS) in patients with COVID-19 pneumonia

Click here ­to­ read full press release/ article 

 Ref: Novartis | Image: Novartis